PACE：ホルモン受容体陽性／ヒト上皮成長因子受容体陰性進行・再発乳癌におけるシクリン依存性キナーゼ4/6阻害剤およびアロマターゼ阻害剤での進行後のフルベストラント、パルボシクリブ、アベルマブのランダム化第II相試験

Mayerら（木曜）がこの問題を検討した。

www.synapsesocial.com/papers/68e72f63b6db6435876a91da — DOI: https://doi.org/10.1200/jco.23.01940

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer· 2010 · 545 citations
2. A general inefficacy interim monitoring rule for randomized clinical trials· 2010 · 64 citations
3. Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial· 2019 · 11 citations
4. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.· 2023 · 72 citations
5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,244 citations